Chae Ok Yun, Founder & CEO – GeneMedicine
Founder and CEO of GeneMedicine, Dr Chae-Ok Yun, explains how the company, specialised in oncolytic virus development, has progressed since we last interviewed her two years ago, with one of…
Address: Room A-101, Namsong Bldg., 260-199 Itaewon-dong, Yongsan-gu Seoul, 140-200, Republic of Korea
Tel: +82 2 796 1056
Web: http://crm.cegedim.com/Pages/default.aspx
Cegedim was created in 1969 by Jean-Claude Labrune, a French visionary entrepreneur who focused on the pharmaceutical industry to provide companies with tailored services that help them build successful commercial strategies. In the late 70’s the first Customer Relationship Management solution designed for the Pharmaceutical industry was launched in France and quickly became a standard. With the success of its solutions, Cegedim quickly expanded its business internationally. In May 2007, Cegedim reinforced its global presence and leadership with the acquisition of Dendrite International, a US based company leading the SFA business in the healthcare sector on its continent as well as in Asia. This successful integration gave birth to a uniquely capable global entity providing Life Sciences ready CRM solutions. Today the new company renamed Cegedim Relationship Management does business in over 80 countries and accounts for more than 50 percent of the Cegedim Group’s annual revenues of $1.1 billion. Around the world, Cegedim Relationship Management works with companies behind the scenes to develop the most appropriate solutions that effectively manage the complex regulatory environment, minimize risks and decrease costs. Laurent Labrune, Group founder’s son, is the Chief Executive Officer of the new global organisation since 2007. He brought a wealth of creativity, innovation and expertise with a strong and knowledgeable management team. Altogether, they effectively made strategic choices for the long term leadership of the company.
Founder and CEO of GeneMedicine, Dr Chae-Ok Yun, explains how the company, specialised in oncolytic virus development, has progressed since we last interviewed her two years ago, with one of…
Eutilex’s CEO, Byoung S. Kwon, outlines the company’s approach to cancer research, including its antibodies and CAR-T-centred pipeline and focus on unmet needs. He also explains recent partnerships in China.…
The latest healthcare and pharma news from South Korea, including SK Bioscience’s COVID-19 vaccine, Daewoong’s partnership with AstraZeneca Korea and UCI Therapeutics, Vivozon production halt and GC’s acquistion of US-based…
Chair & Founder, Regenerative Medicine Acceleration Foundation (RMAF), So Ra Park MD, PhD*, comments on the regenerative medicine ecosystem in Korea, the country’s new legislative approach to the field, and…
KHIDI’s Soonman KWON outlines the public health R&D funding landscape in Korea, plans to increase Korea’s capacity to develop and produce its own vaccines in the wake of the COVID-19…
Two decades ago, South Korean company Celltrion embarked on a quest to find the necessary resources to produce biopharmaceuticals. It took five years for their manufacturing plant to receive GMP…
Boasting a pharma market size of KRW 23.2 trillion (USD 19.2 billion) for 2020, South Korea is one of Asia’s leading pharma nations. Read on for a ranking of the…
Amid global supply shortages and shipment delays for COVID-19 vaccines, South Korea has launched an ambitious 2.2 trillion won (USD 1.9 billion) investment plan to become one of the world’s…
Francis Van Parys, vice president commercial Asia-Pacific at Cytiva, a global life sciences leader dedicated to advancing and accelerating therapeutics, highlights the firm’s tireless work to meet the exponential demand…
The latest news from Korean pharma, including how Korea can put the infrastructure in place to develop a homegrown blockbuster drug; Prestige Biopharma’s move to open a vaccine facility; and…
Joong Myung Cho of Korean biotech success story CrystalGenomics introduces the company’s unique drug discovery platform, key growth factors, highly promising R&D pipeline, and internationalisation plans. We were the…
Young-Shik Cho, chairman of SD Biosensor, recounts his journey leading diagnostics companies and expanding their offerings through R&D. Cho also compares the challenges of the Chinese market with the potential…
See our Cookie Privacy Policy Here
